RImAb: SOLID CANCER IMMUNOTHERAPY

First-in-class antibody that reverts tumor induced immune tolerance by targeting M2 macrophages in solid cancers



UNMET NEED

Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.

Tumor-Associated Macrophage (TAMs) infiltration correlates negatively with survival in cancer and presence of M2 macrophages correlates with a poor prognostic in many types of cancer. Thereby, TAM targeting is emerging as a promising therapeutic strategy for cancer.

OUR SOLUTION

RImAb is an immunotherapy treatment based on monoclonal antibody that blocks CD5L M2-polarizing activity. This treatment aims to reprogram tumor-associated macrophages (TAM) from their anti-inflammatory, tumor promoting state (M2) to a more tumor killing, pro-inflammatory profile (M1).

This immunotherapy would be a first-in-class drug targeting CD5L in Lung and Liver Cancer, among other solid cancers.

THE ASSET

Mechanism of action:
Monoclonal antibody – CD5L
TAM reprogramming

Potential indications:
Antineoplastic agent
Immunotherapy

IP Protection:
PCT/EP2018/079751

Business model:
Sub-license
Acquisition

MARKET & BUSINESS MODEL

Lung Cancer Market: $19.2 B with expected CAGR of 5,5%

Liver Cancer Market: $1.0 B with expected CAGR of 17,7%

Key advantages

- ✓ First-in-class monoclonal antibody
- ✓ No competitors in the market targeting either CD5L or M2 macrophage for cancer treatments
- ✓ Potentially complementary or superior to current treatments or other immunotherapies
- ✓ Applicable for other types of solid tumors
- ✓ Less adverse events compared to other TAM targeted strategies

OPPORTUNITY

License out | Co-development | Spin-off generation

CONTACT

innovation@igtp.cat

Innovation & Business Development Unit

SCIENTIFIC LEADER

mrsarrias@igtp.cat

Maria Rosa Sarrias
Innate Immunity Group

INNOVATION
Germans Trias i Pujol Research Institute